FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3104394536> ?p ?o ?g. }

• W3104394536 abstract "Background Almost 1 in 6 malignant brain cancers are Glioblastoma Multiforme, relative to most other brain cancers it is the most aggressive and prevalent by the numbers. 1 Even with the best treatment options median Overall Survival(OS) remains morbid at 14.6 months and Progression Free Survival(PFS) remains 6.9 months. 2 Telomerase Reverse Transcriptase promoter mutations, 3 Isocitrate Dehydrogenase(IDH) mutations, 4 and Tumor Mutation Burden(TMB) 5 are three prominent tumor markers that are known to be associated with better PFS and OS; markers like these in the presence of new therapies maybe prove crucial to the development of novel therapies. Immunotherapy has been dubbed a ‘game changer’ in certain hematological and solid malignancies. Specifically, PD1 is a glycoprotein that is a strong negative regulator of the immune system, by blocking this glycoprotein Anti-PD-1 agents harness a strong response by the immune system to fight a malignancy 6 . In conjunction with these new found tumor markers, Anti-PD-1 agents maybe the solution that could dramatically improve OS and PFS in these patients. Methods The goal of this study was to retrospectively analyze patients‘ charts who had received Anti-PD-1 therapy and had TERT promoter mutations, IDH mutations, different TMBs, and other markers and to compare their OS and PFS outcomes with conventional therapies and their response to immunotherapy. Results Upon analyzing the data the presence of a TERT promoter 124C>T mutation, IDH wildtype, and lower TMB gave much better OS and PFS after treatment in patients on Anti-PD1 therapy. Conclusions Although this was a small study, these results certainly can be used to examine larger subsets of patients with these markers receiving immunotherapy because they had definitively better outcomes as compared to status quo treatment options. Ethics Approval The study was approved by Washington University Ethics Board, approval number 201111001. References Davis, M.E., Glioblastoma: overview of disease and treatment. Clinical journal of oncology nursing , 2016;20(5 Suppl): p. S2–S8. Stupp R, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352(10): p. 987–996. Mosrati MA, et al., TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015;6(18): p. 16663–16673. Chen J-R., et al., Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas. Medicine , 2016;95(9): p. e2583–e2583. Wu Y, et al. The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis. Frontiers in Oncology 2019;9:p. 1161–1161. Almåsbak H, Aarvak T, and Vemuri MC, CAR T. Cell Therapy: a game changer in cancer treatment. Journal of Immunology Research 2016;2016:p. 5474602–5474602." @default.
• W3104394536 created "2020-11-23" @default.
• W3104394536 creator A5034837880 @default.
• W3104394536 creator A5089841873 @default.
• W3104394536 date "2020-11-01" @default.
• W3104394536 modified "2023-10-16" @default.
• W3104394536 title "214 The effect of Anti-PD-1 therapy on median overall survival and progression free survival in glioblastoma multiforme patients with certain tumor markers" @default.
• W3104394536 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0214" @default.
• W3104394536 hasPublicationYear "2020" @default.
• W3104394536 type Work @default.
• W3104394536 sameAs 3104394536 @default.
• W3104394536 citedByCount "0" @default.
• W3104394536 crossrefType "journal-article" @default.
• W3104394536 hasAuthorship W3104394536A5034837880 @default.
• W3104394536 hasAuthorship W3104394536A5089841873 @default.
• W3104394536 hasBestOaLocation W31043945361 @default.
• W3104394536 hasConcept C104317684 @default.
• W3104394536 hasConcept C121608353 @default.
• W3104394536 hasConcept C126322002 @default.
• W3104394536 hasConcept C127848430 @default.
• W3104394536 hasConcept C142724271 @default.
• W3104394536 hasConcept C143998085 @default.
• W3104394536 hasConcept C181199279 @default.
• W3104394536 hasConcept C203014093 @default.
• W3104394536 hasConcept C2776194525 @default.
• W3104394536 hasConcept C2777150147 @default.
• W3104394536 hasConcept C2777701055 @default.
• W3104394536 hasConcept C2778227246 @default.
• W3104394536 hasConcept C2779130545 @default.
• W3104394536 hasConcept C2779399171 @default.
• W3104394536 hasConcept C2780739268 @default.
• W3104394536 hasConcept C2781230642 @default.
• W3104394536 hasConcept C3019894029 @default.
• W3104394536 hasConcept C501734568 @default.
• W3104394536 hasConcept C502942594 @default.
• W3104394536 hasConcept C55493867 @default.
• W3104394536 hasConcept C71924100 @default.
• W3104394536 hasConcept C86803240 @default.
• W3104394536 hasConcept C8891405 @default.
• W3104394536 hasConceptScore W3104394536C104317684 @default.
• W3104394536 hasConceptScore W3104394536C121608353 @default.
• W3104394536 hasConceptScore W3104394536C126322002 @default.
• W3104394536 hasConceptScore W3104394536C127848430 @default.
• W3104394536 hasConceptScore W3104394536C142724271 @default.
• W3104394536 hasConceptScore W3104394536C143998085 @default.
• W3104394536 hasConceptScore W3104394536C181199279 @default.
• W3104394536 hasConceptScore W3104394536C203014093 @default.
• W3104394536 hasConceptScore W3104394536C2776194525 @default.
• W3104394536 hasConceptScore W3104394536C2777150147 @default.
• W3104394536 hasConceptScore W3104394536C2777701055 @default.
• W3104394536 hasConceptScore W3104394536C2778227246 @default.
• W3104394536 hasConceptScore W3104394536C2779130545 @default.
• W3104394536 hasConceptScore W3104394536C2779399171 @default.
• W3104394536 hasConceptScore W3104394536C2780739268 @default.
• W3104394536 hasConceptScore W3104394536C2781230642 @default.
• W3104394536 hasConceptScore W3104394536C3019894029 @default.
• W3104394536 hasConceptScore W3104394536C501734568 @default.
• W3104394536 hasConceptScore W3104394536C502942594 @default.
• W3104394536 hasConceptScore W3104394536C55493867 @default.
• W3104394536 hasConceptScore W3104394536C71924100 @default.
• W3104394536 hasConceptScore W3104394536C86803240 @default.
• W3104394536 hasConceptScore W3104394536C8891405 @default.
• W3104394536 hasLocation W31043945361 @default.
• W3104394536 hasOpenAccess W3104394536 @default.
• W3104394536 hasPrimaryLocation W31043945361 @default.
• W3104394536 hasRelatedWork W10138567 @default.
• W3104394536 hasRelatedWork W11687661 @default.
• W3104394536 hasRelatedWork W11740975 @default.
• W3104394536 hasRelatedWork W13487282 @default.
• W3104394536 hasRelatedWork W14576825 @default.
• W3104394536 hasRelatedWork W20092512 @default.
• W3104394536 hasRelatedWork W3586383 @default.
• W3104394536 hasRelatedWork W3706229 @default.
• W3104394536 hasRelatedWork W5786864 @default.
• W3104394536 hasRelatedWork W828048 @default.
• W3104394536 isParatext "false" @default.
• W3104394536 isRetracted "false" @default.
• W3104394536 magId "3104394536" @default.
• W3104394536 workType "article" @default.